MedTrace Logo

Bayer/Cognitive Assessments With Multiple Sclerosis Subjects

NCT00888277 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 74

Last updated 2013-11-04

No results posted yet for this study

Summary

This study is designed to identify a brief screening evaluation for MS patients that is sensitive and specific to the MS population and which correlates with the findings of our standard-of-care neuropsychological assessments.

Conditions

  • Multiple Sclerosis, Relapsing-remitting
  • Multiple Sclerosis, Secondary Progressive

Sponsors & Collaborators

  • Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

    collaborator INDUSTRY

  • University of Louisville

    lead OTHER

Principal Investigators

  • Richard Kirzinger, MD · University of Louisville

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2009-12-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00888277 on ClinicalTrials.gov